Other languages Chiome Bioscience Inc.

Equities

4583

JP3205350006

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-02 EDT			5-day change	1st Jan Change
123 ^JPY	-2.38%		0.00%	-8.89%

04-01	Chiome Bioscience Cancels License Agreements with ADC Therapeutics	MT
02-13	Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited	02-13
Chiome Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-13
Chiome Bioscience Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	11-14
Chiome Bioscience Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-09
Chiome Bioscience Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Chiome Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-14
Chiome Bioscience Inc. Provided Sales Guidance for 2023	23-02-14
Chiome Bioscience Inc. Announces Termination of the License Agreement for Anti-TROP-2 Antibody Development and Commercialization with Shanghai Henlius Biotech, Inc	23-01-17
Chiome Bioscience Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-11-14
Heidelberg Pharma Enters Research Collaboration Deal With Japan's Chiome Bioscience	22-07-13
Chiome Bioscience Inc. Announces Conclusion of Target-Specific Research and Option Agreement with Heidelberg Pharma	22-07-13
Japan Index Snaps Three-day Winning Streak on Inflationary Pressures; Kudan Shares Expand 7%	22-07-12
Chiome Bioscience Inc. Announces Service Agreement with Option Contract with Rohto Pharmaceutical Co., Ltd	22-07-11
Chiome Bioscience Inc. Announces First Patient in of Cancer Therapeutic Antibody CBA-1535 in A Phase 1 Clinical Trial	22-07-04
Chiome Bioscience Inc. Announces Conclusion of Contract with Additional Institutes and First Dosing of CBA-1205 in the Second Part of Phase 1 Study	22-06-13
Japan Index Trims Gains over Inflationary Pressures; Dena to Take Majority Stake in Mobile ICT Business for $230 Million	22-05-27
Chiome Bioscience Inc. Submits an Initial Application for Phase I Study on CBA-1535	22-02-16
Chiome Bioscience Inc. and Fujirebio, Inc. Enter into License Agreement	22-02-15
Chiome Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-14
Chiome Bioscience Inc. Announces Move to the Second Half Part of Phase 1 Clinical Trial of First-In-Class CBA-1205	21-12-24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Chiome Bioscience Inc.

Equities

4583

JP3205350006

Other languages

Filters